Monday’s NASDAQ trade opportunity

Pre-Merger, Tiny float and trading just above 52-week lows at .88/share


Good day everyone,

Spherix to Merge with CBM BioPharma, Inc.


UPDATE 11/26/18*** Acquisition announced this morning – Spherix Announces Ownership Interest in Electric Scooter Business, SPEX announced 25% ownership in Mellow full PR –


Today we are initiating coverage on Spherix Incorporated (NASDAQ: SPEX). We believe the pending merger of Spherix Incorporated and CBM Biopharma, Inc. could propel SPEX shares to considerable gains creating significant shareholder value.


Current price                                  $.88 per share

Outstanding shares (est.)             8.56 million

Float (est.)                                      8.44 million shares

52-week range                               $.78 to $2.42 per share

Insiders are currently (last week) buying shares.


Last month, SPEX announced that it entered into a merger agreement with CBM BioPharma, Inc. that will transform Spherix into an innovative pharmaceutical company with pioneering drugs and treatments focused on the multibillion-dollar oncology therapeutics market.


CBM BioPharma, Inc is a privately held company with exclusive drug development rights from Wake Forest Innovations and the University of Texas. The CBM BioPharma, Inc platform focuses on the treatment of numerous cancers, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and pancreatic cancer.


CBM has two specific proprietary oncology drugs that are currently being researched


KPC34 (Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia) is a next generation treatment designed to overcome multiple resistance challenges observed with the current standard of care. KPC34 has also been shown to be more effective in AML relapse cases, notably increasing the lifespan of mice treated with the drug.


One competitive benefit of KPC34 includes its ability to be orally administered. This is critical for patients that are unable to tolerate repeated cycles of chemotherapy. In addition, it has served to double the mean survival time of patients versus the current standard of care treatments. DOUBLED.

The video at the link below shows remarkable results in a mouse treated with KPC34.


DHA-dFdC (Pancreatic Cancer Drug) has shown positive results in preclinical studies, inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models. DHA-dFdC also overcomes tumor cell resistance to current chemotherapeutic drugs.  Pancreatic cancer is a deadly disease that affects millions of people around the world.


Pre-clinical studies done with these two CBM drugs have shown great promise. SPEX has been transitioning its focus and efforts toward becoming a technology development company for the entirety of 2018.


Last month, SPEX added Dr. Rana Quraishi to the Company’s Advisory Board to assist the Company in evaluating potential opportunities in the biopharmaceutical area.


Spherix also owns, develops, acquires, and monetizes patented and unpatented intellectual properties. The company owns approximately 290 patents and patent applications in the wireless communications and telecommunication sectors. SPEX has filed several patent infringement suits and has been awarded substantial settlements and licensing agreements.


SPEX has other investments including Hoth Therapeutics Inc., a biopharmaceutical company focused on BioLexa, developed at the University of Cincinnati for patients suffering from eczema. According to the National Eczema Association, eczema affects approximately 32 million Americans and represents a $9.5 billion market in the U.S. alone.


The CBM merger is a continuance into the biopharma sector begun with the Hoth investment.


Earlier this year SPEX invested in DatChat, a company involved in online security, Ethereum mining and a newsletter ( that apprises users on the latest updates and events impacting the blockchain and cryptocurrencies sectors.


Recent Insider Buying 

Last week insiders purchased 20,000 shares of SPEX stock, including CEO Anthony Hayes. In fact, the last nine insider transactions, dating back to May of 2017, have been buys/acquisitions.




The surviving company in the merger will be CBM so all current and future SPEX shareholders will have an opportunity to own shares in a biopharma company with three promising drug products.


SPEX shares are currently trading at 63% off their 52-week high and only 12% over their 52-week low.


SPEX shares are trading below their 50 DMA and their 200 DMA of $.95 and $1.07 respectively. The current RSI (14) is 44.60. These data indicate shares that may be oversold.


The Traders News Group



Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. TNS LLC’s parent company has been compensated twenty five thousand dollars cash via bank wire by Horizon management consultants LLC for this weeks coverage of SPEX. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.